Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume3
DOIs
StatePublished - 2016

Keywords

  • Alzheimer's disease
  • Autopsy
  • Ceramide
  • Lewy body
  • Lipids

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology'. Together they form a unique fingerprint.

Cite this